

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re patent application of:

C. Lowenstein, et al.

Confirmation No. 2022

Serial No: 10/553,686

Group Art Unit: 1652

Filed: 11/3/2006

Examiner: not assigned

For: Inhibitors of n ethylmaleimide sensitive factor

Box: Appln. Branch
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450


REQUEST FOR CORRECTED OFFICIAL FILING RECEIPT

Sir:

This is a request to provide the undersigned with a "corrected" Official Filing Receipt for the above application. Attached is the filing receipt in which a word in the title (page 2) contains a spelling error. More specifically, please delete "ethymaleimide" and insert -- ethylmaleimide -- . This is a '371 application and attached is a copy of the first page of the international application showing the title.

Since the typographical error was a PTO error, no fee is submitted. If it is determined that a fee is due, please charge Deposit Account No. 50-2041.

Respectfully submitted,



Michael E. Whitham
Reg. No. 32,635

Date: June 10, 2010
Whitham, Curtis, Christofferson & Cook, PC
11491 Sunset Hills Road - #340
Reston, VA 20190
703/787-9400
Customer No.: 30743



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov



APPLICATION NUMBER	FILING or 371(c) DATE	OR PART UNIT	FILED REC'D	ATTY DOCKET NO	TOT CLAIMS	IND CLAIMS
10/553,686	11/03/2006	1652	1395	07410010AA	53	2

CONFIRMATION NO. 2022

FILING RECEIPT



0000000041073973

30743
WHITHAM, CURTIS & CHRISTOFFERSON & COOK, P.C.
11491 SUNSET HILLS ROAD
SUITE 340
RESTON, VA 20190

Date Mailed: 06/02/2010

Receipt is acknowledged of this non-provisional patent application. The application will be taken up for examination in due course. Applicant will be notified as to the results of the examination. Any correspondence concerning the application must include the following identification information: the U.S. APPLICATION NUMBER, FILING DATE, NAME OF APPLICANT, and TITLE OF INVENTION. Fees transmitted by check or draft are subject to collection. Please verify the accuracy of the data presented on this receipt. If an error is noted on this Filing Receipt, please submit a written request for a Filing Receipt Correction. Please provide a copy of this Filing Receipt with the changes noted thereon. If you received a "Notice to File Missing Parts" for this application, please submit any corrections to this Filing Receipt with your reply to the Notice. When the USPTO processes the reply to the Notice, the USPTO will generate another Filing Receipt incorporating the requested corrections.

Applicant(s)

Charles Lowenstein, Silver Spring, MD;
Kenji Matsushita, Baltimore, MD;
Craig Morrell, Baltimore, MD;

Power of Attorney: The patent practitioners associated with Customer Number 30743

Domestic Priority data as claimed by applicant

This application is a 371 of PCT/US04/11655 04/15/2004
which claims benefit of 60/463,395 04/15/2003

Foreign Applications

If Required, Foreign Filing License Granted: 04/18/2007

The country code and number of your priority application, to be used for filing abroad under the Paris Convention, is **US 10/553,686**

Projected Publication Date: Not Applicable

Non-Publication Request: No

Early Publication Request: No

**** SMALL ENTITY ****

Title

Inhibitors of ~~ne~~ ^{ethylmaleimide} thymalimide sensitive factor

Preliminary Class

514

PROTECTING YOUR INVENTION OUTSIDE THE UNITED STATES

Since the rights granted by a U.S. patent extend only throughout the territory of the United States and have no effect in a foreign country, an inventor who wishes patent protection in another country must apply for a patent in a specific country or in regional patent offices. Applicants may wish to consider the filing of an international application under the Patent Cooperation Treaty (PCT). An international (PCT) application generally has the same effect as a regular national patent application in each PCT-member country. The PCT process **simplifies** the filing of patent applications on the same invention in member countries, but **does not result** in a grant of "an international patent" and does not eliminate the need of applicants to file additional documents and fees in countries where patent protection is desired.

Almost every country has its own patent law, and a person desiring a patent in a particular country must make an application for patent in that country in accordance with its particular laws. Since the laws of many countries differ in various respects from the patent law of the United States, applicants are advised to seek guidance from specific foreign countries to ensure that patent rights are not lost prematurely.

Applicants also are advised that in the case of inventions made in the United States, the Director of the USPTO must issue a license before applicants can apply for a patent in a foreign country. The filing of a U.S. patent application serves as a request for a foreign filing license. The application's filing receipt contains further information and guidance as to the status of applicant's license for foreign filing.

Applicants may wish to consult the USPTO booklet, "General Information Concerning Patents" (specifically, the section entitled "Treaties and Foreign Patents") for more information on timeframes and deadlines for filing foreign patent applications. The guide is available either by contacting the USPTO Contact Center at 800-786-9199, or it can be viewed on the USPTO website at <http://www.uspto.gov/web/offices/pac/doc/general/index.html>.

For information on preventing theft of your intellectual property (patents, trademarks and copyrights), you may wish to consult the U.S. Government website, <http://www.stopfakes.gov>. Part of a Department of Commerce initiative, this website includes self-help "toolkits" giving innovators guidance on how to protect intellectual property in specific countries such as China, Korea and Mexico. For questions regarding patent enforcement issues, applicants may call the U.S. Government hotline at 1-866-999-HALT (1-866-999-4158).

LICENSE FOR FOREIGN FILING UNDER

Title 35, United States Code, Section 184

Title 37, Code of Federal Regulations, 5.11 & 5.15

GRANTED

The applicant has been granted a license under 35 U.S.C. 184, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" followed by a date appears on this form. Such licenses are issued in all applications where the conditions for issuance of a license have been met, regardless of whether or not a license may be required as

(19) World Intellectual Property
Organization
International Bureau



(43) International Publication Date
28 October 2004 (28.10.2004)

PCT

(10) International Publication Number
WO 2004/091534 A2

- (51) International Patent Classification⁷: **A61K**
- (21) International Application Number:
PCT/US2004/011655
- (22) International Filing Date: 15 April 2004 (15.04.2004)
- (25) Filing Language: English
- (26) Publication Language: English
- (30) Priority Data:
60/463,395 15 April 2003 (15.04.2003) US
- (71) Applicant (for all designated States except US): **THE
JOHNS HOPKINS SCHOOL OF MEDICINE**
[US/US], 100 N. Charles Street, 5th Floor, Baltimore, MD
21201 (US).
- (72) Inventors; and
- (73) Inventors/Applicants (for US only): **LOWENSTEIN,**





Charles [US/US], 1706 Tilton Drive, Silver Spring,
MD 20902 (US); **MATSUSHITA, Kenji** [JP/US], 6603
Copperridge Drive, Apt. 101, Baltimore, MD 21209
(JP); **MORRELL, Craig** [CA/US], 2917 St. Paul Street,
Baltimore, MD 21218 (US).

(74) Agents: **WHITHAM, Michael, E. et al.**; Whitham, Curtis
& Christofferson, P.C., 11491 Sunset Hills Road, Suite 340,
Reston, VA 20190 (US).

(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN,
CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI,
GB, GD, GE, GH, GM, GR, GU, HK, IL, IN, IS, JP, KE,
KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD,
MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG,
PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM,
TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM,
ZW.

[Continued on next page]

(54) Title: INHIBITORS OF N-ETHYLMALEIMIDE SENSITIVE FACTOR



(57) Abstract: Methods and compositions for blocking exocytosis by inhibition of proteins that regulate exocytosis, such as N-ethylmaleimide Sensitive Factor (NSF), are provided. The compositions include multi-domain fusion peptides containing a domain that causes the fusion peptide to cross the cellular membrane (e.g., a domain from the TAT protein of HIV) and a domain that inhibits NSF (e.g., a domain of NSF). Administration of the fusion peptide promotes anticoagulation, attenuates thrombosis, and decreases heart attack severity.

COPY